CellCentric – $220M Financing for Inobrodib

Summary CellCentric has raised $220 million in a Series D financing to advance inobrodib, an oral p300/CBP inhibitor for multiple myeloma, supporting ongoing Phase 2 studies and planned Phase 3 development. What Happened The financing will fund late-stage clinical development and potential commercialization activities for…